Research
Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers
The Brief
- A Phase I trial of the investigational antibody-drug conjugate micvotabart pelidotin (MICVO, PYX-201) showed promising antitumor activity in head and neck cancers.
- The trial reported a manageable safety profile.
- The results were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Why it matters
This is early-stage evidence from a Phase I trial, so it shows initial activity and safety rather than efficacy, and science readers should watch for later-phase results before drawing conclusions about treatment benefit.
Who’s affected
- oncologists and head and neck cancer researchers
- drug developers working on antibody-drug conjugates
The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase I trial presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics by…